A5044492227- Lipoproteins and Cardiovascular Health
- Pharmaceutical Economics and Policy
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Birth, Development, and Health
- Biosimilars and Bioanalytical Methods
- Eating Disorders and Behaviors
- Acute Myocardial Infarction Research
- Pharmacological Effects of Natural Compounds
- Neurological Complications and Syndromes
- Systemic Lupus Erythematosus Research
- Congenital Heart Disease Studies
- Hormonal Regulation and Hypertension
- Estrogen and related hormone effects
- Ovarian function and disorders
- Asthma and respiratory diseases
- Cardiovascular Issues in Pregnancy
- Aortic Thrombus and Embolism
- Neurosurgical Procedures and Complications
- Bariatric Surgery and Outcomes
- Psoriasis: Treatment and Pathogenesis
- Nutritional Studies and Diet
- Systemic Sclerosis and Related Diseases
- Ginkgo biloba and Cashew Applications
- Cancer, Lipids, and Metabolism
Erasmus MC
2019-2025
Erasmus MC Hart en Vaat Instituut
2023
Erasmus University Rotterdam
2023
Accommodating fetal growth and development, women undergo multiple physiological changes during pregnancy. In recent years, several studies contributed to the accumulating evidence about impact of gestational hyperlipidemia on cardiovascular risk for mother child. This review aims provide a comprehensive overview current research lipid profile alterations pregnancy its associated (cardiovascular) outcomes child from clinical perspective.
•Inclisiran lowers LDL-C by -38 % at 3 months in real-world setting.•Patients who use statin co-medication had a greater reduction of -45 %.•Most patients switching from PCSK9 mAbs to inclisiran showed an increase LDL-C.•Inclisiran has favourable safety profile setting and 9 follow-up. Background objectiveInclisiran is the first-in-class small interfering RNA (siRNA) proprotein convertase subtilisin kexin type (PCSK9) inhibitor. In clinical trials effective sustained low-density lipoprotein...
Proprotein convertase subtilisin/kexin 9 monoclonal antibodies (PCSK9 mAbs) reduce low-density lipoprotein (LDL-c) with a favourable safety profile. Available data from PCSK9 antibody trials suggest LDL-c reduction is lower in women compared to men. Data real-world setting scarce. The aim of this study was assess sex differences efficacy and clinical care.All patients starting evolocumab or alirocumab our lipid clinic were included prospective registry. We collected information, including...
Homozygous familial hypercholesterolemia (HoFH) is characterized by extremely high plasma low-density lipoprotein cholesterol (LDL-C) levels and premature atherosclerotic cardiovascular disease risk. During pregnancy LDL-C increase, while limited therapeutic options are available. This international study documented current approaches of healthcare professionals (HCPs) to family planning, pregnancy, breastfeeding in HoFH. An online HCP survey was distributed among the HoFH International...
Early and lifelong treatment is essential in patients with familial hypercholesterolaemia (FH) due to genetically elevated low-density lipoprotein cholesterol (LDL-C) from the first years of life. In women FH, lipid-lowering interrupted during childbearing contraindication medication conception, pregnancy breastfeeding. However, little known about impact breastfeeding on lipid profile other risk markers for atherosclerotic cardiovascular disease (ASCVD) FH compared without...
Homozygous familial hypercholesterolemia (HoFH) is characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels leading to extremely premature atherosclerotic cardiovascular disease. Therefore, healthcare professionals consider HoFH have major impact on patients' life. Remarkably, little known how patients deal with their condition. The aim of this study investigate Dutch experience and cope in daily life.Adult genetically confirmed HoFH, treated at the 3 specialized...
Abstract Background Inclisiran is the first-in-class small interfering RNA (siRNA) PCSK9 inhibitor. In clinical trials, inclisiran showed effective and sustained LDL-C reduction of approximately 50%. However, data about efficacy safety in setting are scarce. We aim to investigate practice. Methods Registry all consecutive patients who started with at a lipid clinic university hospital. Patients were eligible if they fulfilled reimbursement criteria Netherlands; very high risk FH and/or ASCVD...
Abstract Background Previous studies showed fluctuating lipid levels during the menstrual cycle in healthy women with normal cholesterol (nChol). Cycle-related variations familial hypercholesterolemia (FH) have not been studied, while these might important consequences for management. Purpose To investigate cycle-related fluctuations FH compared to those nChol. Methods In Netherlands and Norway, 20 clinical/genetic 63 nChol were included - details are presented figures. Participants had a...